Home Reports Health and Medicine Content

Genetic Testing Could Identify HIV Patients At Risk Of Hypersensitivty To HIV Drug

next article

01.03.2002

HIV patients at risk of a potentially fatal hypersensitive reaction to the antiretroviral drug abacavir could be identified by genetic testing before drug therapy has started, suggest authors of a fast-track study in this week’s issue of THE LANCET.

The use of the HIV antiretroviral drug abacavir, a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might result in some individuals being more susceptible to a hypersensitive reaction than other patients.

Simon Mallal and colleagues from the Royal Perth Hospital, Australia, studied 200 HIV patients treated with abacavir. They focused on analysis of the MHC genes that are known to be associated with the immune response.

Abacavir hypersensitivity was identified in 18 patients, and drug tolerance was confirmed in 167 patients after 6 weeks of therapy. Patients with the allele (gene component) HLA-B*5701 were over 100 times more likely to be hypersensitive to abacavir; this allele was present in 14 (78%) of the 18 patients with abacavir hypersensitivity, and in four (2%) of the 167 abacavir-tolerant patients. The genetic region marked by the combination HLA-B*5701, HLA-DR7, and HLA-DQ3 (the 57.1 ancestral haplotype) was present in 13 (72%) hypersensitive patients and none of the tolerant patients. All patients with the full 57.1 ancestral haplotype experienced abacavir hypersensitivity.

Simon Mallal comments: “The findings have important clinical implications. In our population, withholding abacavir in patients with this haplotype would be expected to reduce the prevalence of this potentially life-threatening event from 9% to 2.5 % without inappropriately denying the drug to any patients. Based on these data it is our current practice to withhold abacavir in patients who have the HLA-B*5701,-DR7,-DQ3 haplotype. However, before such practice can be taken up by others it is essential that the association between HLA type and abacavir hypersensitivity in their own populations is assessed.”

He adds: “However, there were four patients in the study who developed abacavir hypersensitivity in whom no part of the susceptibility haplotype could be identified. Therefore, HLA typing at these alleles could not be used to completely exclude the risk of a future reaction, and the current clinical approach of high vigilance for these reactions must continue.”

In an accompanying Commentary (p 722), Amalio Telenti from University Hospital, Lausanne, Switzerland,concludes: “From recent developments in human genetics, a need for a more comprehensive analysis, including dozens or hundreds of genes, can be predicted. This analysis may become feasible by use of microarrays that allow interrogation of multiple genes simultaneously. Decisions about the best time to start therapy, and the most effective and least toxic drug combinations, may be based on particular genotype profiles. This projection may look far-fetched, with just a few relevant genes identified, but these are the first drops before a downpour.”

Richard Lane | Source: alphagalileo

next article